Rhabdoid Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Rhabdoid Tumor (RT) is a rare and aggressive pediatric soft tissue sarcoma that can arise in various body parts, including the kidney, liver, peripheral nerves, and miscellaneous soft tissues. RT affecting the central nervous system is referred to as Atypical Teratoid Rhabdoid Tumor (ATRT). In most RT cases, there is biallelic inactivation of the SMARCB1 gene, a tumor suppressor gene involved in regulating the expression of the genome. In rare cases, RT is associated with biallelic mutations in the SMARCA4 gene, another SWI/SNF chromatin remodeling complex member. RT commonly occurs in infancy or childhood, with most cases occurring in patients younger than two years old. The first symptoms are usually linked to the compressive effects of a large tumor, such as respiratory distress, abdominal mass, or peripheral nerve palsy. Subcutaneous nodular metastases are a specific feature of neonatal RT cases. Diagnosis is based on imaging scans and confirmed by biopsy and immunohistochemistry. The tumor is composed of cells with eccentric nuclei, prominent nucleoli, and eosinophilic cytoplasm. The prognosis for RT is poor, with a 5-year survival rate of only 20%. Factors that negatively impact prognosis include metastases, young age at diagnosis, and incomplete resection. ATRT is the most frequent malignant tumor of the posterior fossa in the same age range. In infants less than one-year-old, RT may account for 20% of renal cancers and 15% of soft-part tumors.

·       In the UK estimated age-standardized annual incidence of extra-CNS Rhabdoid tumor is 1/2,000,000 children.

Thelansis’s “Rhabdoid Tumor Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Rhabdoid Tumor treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Rhabdoid Tumor across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Rhabdoid Tumor Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Rhabdoid Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033